What ESC 2021 guidelines say about use of Mineralocorticoid Receptor Antagonist (MRA) in HFrEF?
Advertisement
The European Society of Cardiology (ESC) has recently issued guidelines to include Mineralocorticoid Receptor Antagonist (MRA) besides ACE-I and beta-blockers, in all patients with HFrEF to reduce mortality and the risk of HF hospitalization (class 1A recommendation). The aim of this ESC Guideline is to help health professionals manage people with heart failure (HF) according to the best available evidence.
In this video, Dr. Prem Aggarwal a senior cardiologist, New Delhi gives an insight into the new guidelines and recommendations by ESC while also discussing the treatment modalities for patients with HF.
For more details, check out the below mentioned link:
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.